Exagen to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

September 12, 2023 | Last Trade: US$11.61 0.16 -1.36

SAN DIEGO, California, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2023 Cantor Fitzgerald Global Healthcare Conference, which takes place September 26-28, 2023, at the InterContinental Barclay Hotel in New York City. John Aballi, Exagen’s President and Chief Executive Officer and Kamal Adawi, Exagen’s Chief Financial Officer, will participate in a panel discussion on Tuesday, September 26^th, at 8:45 AM ET. Interested parties may access the webcast of the presentation using a link on Exagen’s website at https://investors.exagen.com/events.

About Exagen Inc.

Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California.

For more information, please visit Exagen.com and follow @ExagenInc on Twitter.

Investor Relations
Exagen Inc.
Ryan Douglas
This email address is being protected from spambots. You need JavaScript enabled to view it.
760.560.1525

Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$11.61
Daily Change:	-0.16 -1.36
Daily Volume:	26,475
Market Cap:	US$255.420M

July 29, 2025 Exagen Reports Strong Q2 2025 Results July 17, 2025 Exagen Appoints Chas McKhann to Board of Directors June 23, 2025 Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics May 09, 2025 Exagen Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares May 07, 2025 Exagen Announces Proposed Public Offering of Common Stock LOAD MORE NEWS

Featured Stock

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE